elranatamab will increase the level or impact of ergotamine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Elranatamab brings about cytokine launch syndrome (CRS) that could suppress action of CYP enzymes, leading to elevated exposure of CYP substrates.Etizolam performs by improving signaling of a chemical within the… Read More